DE10158281A1 - Pharmaceutical preparation comprises ginsenoside enclosed in micro-shell, e.g. liposome, providing targeted and controlled delivery, useful e.g. in treatment of liver tumors, diabetes mellitus or hypertension - Google Patents
Pharmaceutical preparation comprises ginsenoside enclosed in micro-shell, e.g. liposome, providing targeted and controlled delivery, useful e.g. in treatment of liver tumors, diabetes mellitus or hypertensionInfo
- Publication number
- DE10158281A1 DE10158281A1 DE2001158281 DE10158281A DE10158281A1 DE 10158281 A1 DE10158281 A1 DE 10158281A1 DE 2001158281 DE2001158281 DE 2001158281 DE 10158281 A DE10158281 A DE 10158281A DE 10158281 A1 DE10158281 A1 DE 10158281A1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical preparation
- preparation according
- therapeutic treatment
- ginsenosides
- ginsenoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Die Erfindung bezieht sich auf ein pharmazeutisches Präparat, enthaltend Inhaltsstoffe von Ginsengextrakten und dessen Verwendung. The invention relates to a pharmaceutical preparation containing Ingredients of ginseng extracts and their use.
Die Ginsengpflanze ist als Heilpflanze durch viele homöopathische Anwendungen bekannt. Den Inhaltsstoffen des Ginsengextraktes werden sehr unterschiedliche Wirkungen zugesprochen. So sollen entsprechende flüssige und feste Zubereitungen die natürliche Widerstandsfähigkeit des Organismus stärken und dessen Erholung nach Belastbarkeit beschleunigen. The ginseng plant is considered a medicinal plant by many homeopathic ones Applications known. The ingredients of the ginseng extract become very awarded different effects. Corresponding liquid and solid preparations strengthen the natural resistance of the organism and accelerate its recovery after resilience.
In der festen Darreichungsform liegen die Extrakte meistens in Form von Kapseln vor, die oral verabreicht werden. Derartige oral verabreichten homöopotische Applikationen machen zunächst eine Leberpassage durch, bevor sie durch den Blutstrom im Organismus verteilt werden. Bei diesem Applikationsweg kann der Wirkstoff weitgehend zu wirksamen Folgeprodukten abgebaut werden, bevor er den beabsichtigten Wirkungsort (Zellen, Gewebe, Organ) erreicht. Die Folge davon ist, dass nicht selten eine höhere Dosis oder mehrfache Injektionen oder orale Verabreichungen pro Tag erforderlich sind, um eine therapeutisch wirksame Konzentration im Körper aufrechtzuerhalten. In the solid dosage form, the extracts are usually in the form of capsules before, which are administered orally. Such orally administered homeopathic Applications first go through a liver passage before they go through the Blood flow can be distributed in the organism. With this application route, the Active ingredient is largely broken down into effective secondary products before it reaches the intended site of action (cells, tissue, organ). The consequence of which is that it is not uncommon for a higher dose or multiple injections or oral administrations per day are required to be therapeutic maintain effective concentration in the body.
Aufgabe der Erfindung ist es daher, ein pharmazeutisches Präparat, enthaltend Inhaltsstoffe von Ginseng-Extrakten mit verbesserter Wirkstoffverfügbarkeit bei minimaler Belastung des restlichen Organismus bereitzustellen. The object of the invention is therefore to contain a pharmaceutical preparation Ingredients of ginseng extracts with improved drug availability to provide minimal stress to the rest of the organism.
Erfindungsgemäß wird die Aufgabe durch ein pharmazeutisches Präparat mit einem Gehalt an Ginsenosiden in Mikroapplikationshüllen gelöst. According to the invention, the object is achieved by a pharmaceutical preparation a content of ginsenosides dissolved in microapplication shells.
Gemäß einer bevorzugten Ausführungsform des pharmazeutischen Präparates sind die Mikroapplikationshüllen durch Liposome oder Nanopartikel gebildet oder weist die Mikroapplikationshülle eine mehrschichtige Membran auf. According to a preferred embodiment of the pharmaceutical preparation are the microapplication shells formed by liposomes or nanoparticles or the microapplication shell has a multilayer membrane.
Eine weitere bevorzugte Ausführungsform der Erfindung sieht vor, dass die Ginsenoside solche der Gruppe Aglykon (20S)-Protopanaxadiol mit den Ginsenosiden Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, den Notoginsenosiden R4, Rs1 und Rs2 und den Malonylginsenosiden Rb1, Rc und Rd und/oder der Gruppe Aglykon (20S)-Protopanaxtriol mit den Ginsenosiden Re, Rf, Rg1 und dem Notoginsenosid R1 und/oder derAglykon Oleanolsäure mit den Ginsenosiden Ro und Chikusetsusasaponin-V sind. Another preferred embodiment of the invention provides that the Ginsenosides from the group Aglykon (20S) -protopanaxadiol with the Ginsenosides Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, the Notoginsenosiden R4, Rs1 and Rs2 and the malonyl ginsenosides Rb1, Rc and Rd and / or the group Aglykon (20S) -protopanaxtriol with the ginsenosides Re, Rf, Rg1 and the Notoginsenoside R1 and / or the aglycon oleanolic acid with the ginsenosides Ro and Chikusetsusasaponin-V are.
Als eine besonders bevorzugte Ausführungsform der Erfindung hat sich das pharmazeutische Präparat mit einem Gehalt an mindestens einem der Ginsenoside R1, R4, Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rs1, Rs2, Ro oder Chikusetsusasaponin-V oder an mehreren der genannten Ginsenoside im Gemisch oder in Kombination mit über an der Mikroapplikationshülle gekoppelte Liganden verbundenen anderen Wirkstoffen erwiesen. This has proven to be a particularly preferred embodiment of the invention pharmaceutical preparation containing at least one of the Ginsenoside R1, R4, Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rs1, Rs2, Ro or Chikusetsusasaponin-V or on several of the above Ginsenosides in a mixture or in combination with above Microapplication-coupled ligands linked to other drugs proved.
Der besondere Vorzug der Erfindung besteht darin, dass erstmals das therapeutische Potential von Mikroapplikationshüllen für Ginsenoside mit der erfindungsgemäßen Lösung in Form eines "Drug Targeting" erschlossen wird. Die neue Applikationsform ermöglicht vielfältige neue Einsatzmöglichkeiten pharmazeutischer Präparate einschließlich von Arzneimitteln mit einem Gehalt an Ginsenosiden und die unterschiedlichen pharmakologischen Wirkungen der Ginsenoside auf effektive Weise auszuschöpfen. The particular advantage of the invention is that for the first time therapeutic potential of microapplication shells for ginsenosides with the solution according to the invention is developed in the form of "drug targeting". The new form of application enables a variety of new uses pharmaceutical preparations, including medicines containing Ginsenosides and the different pharmacological effects of Use ginsenosides effectively.
Mit der Erfindung ist es möglich, das Freigabeverhalten des pharmazeutischen Präparates hinsichtlich der Ginsenoside am Zielort zu optimieren sowie deren Abgaberate zu kontrollieren und die Dauer der Wirksamkeit der Ginsenoside bei den Zielzellen zu steuern. Mittels des erfindungsgemäßen Applikationsweges können die Ginsenoside direkt in das Innere der Zielzelle gebracht werden. Die Ginsenoside sind dadurch vor dem Angriff von Körperflüssigkeiten und damit vor dem Zerfall bei Eingabe in den Organismus geschützt. Sie können am Zielort ihre volle Wirksamkeit entfalten. Durch die "Verpackung" in Mikroapplikationshüllen können die Ginsenoside enthaltenden pharmakologischen Zusammensetzungen erstmals auch intravenös verabreicht werden. With the invention it is possible to control the release behavior of the pharmaceutical To optimize preparations with regard to the ginsenosides at the destination as well as their Control rate of release and duration of effectiveness of ginsenosides to control the target cells. By means of the application route according to the invention the ginsenosides can be brought directly into the interior of the target cell. The Ginsenosides are thus before the attack of body fluids and thus before protected from decay when entered into the organism. You can find yours at the destination unfold full effectiveness. Through the "packaging" in micro-application sleeves can the ginsenosides containing pharmacological compositions can also be administered intravenously for the first time.
Überraschend wurde gefunden, dass einzelne in Mikroapplikationshüllen verpackten Ginsenosiden eine besondere therapeutische Wirkung haben und zur Verwendung als Arzneimittel geeignet sind. Surprisingly, it was found that individual in micro-application cases packaged ginsenosides have a special therapeutic effect and Are suitable as medicinal products.
Hochreine Ginsenoside wurden als Einzelkomponenten in einer HPLC-Anlage isoliert, in Liposomen verpackt und für pharmakologische Studien eingesetzt. In einer derartigen Studie wurde die Wirksamkeit des Ginsenosides Rg1, verpackt in einer Lipid-Formulierung, für die in der Literatur ein Lebertargeting beschrieben ist, an Ratten mit akuter Leberschädigung untersucht. Die Studie wurde mit einer Dosierung von 0,1 mg bis 50,0 mg reinem Ginsenosid Rg1 pro ml Liposom durchgeführt. High-purity ginsenosides were used as individual components in an HPLC system isolated, packaged in liposomes and used for pharmacological studies. The effectiveness of the ginsenoside Rg1, packed in a lipid formulation for which a liver targeting in the literature has been described in rats with acute liver damage. The study was with a dosage of 0.1 mg to 50.0 mg of pure ginsenoside Rg1 pro ml liposome performed.
Bereits nach 7 Tagen war ein Wirkungseintritt festzustellen. Im Ergebnis der Studie konnte unerwartet und überraschend festgestellt werden, dass durch das Ginsenosid Rg1 eine Gewebeerneuerung an der Leber der Ratte bewirkt wurde. Erstmals kann so ein pharmazeutisches Präparat bereitgestellt werden, deren Verwendung für die therapeutische Behandlung von Lebertumoren, Leberzirrhosen und anderen chronischen Lebererkrankungen geeignet ist. The onset of effects was already evident after 7 days. As a result of The study unexpectedly and surprisingly found that the Ginsenoside Rg1 caused tissue renewal in the liver of the rat. For the first time, a pharmaceutical preparation can be made available whose Use for the therapeutic treatment of liver tumors, Cirrhosis of the liver and other chronic liver diseases is suitable.
Studien haben des weiteren ergeben, dass erfindungsgemäße pharmazeutische Präparate mit einem Gehalt an dem Ginsenosid Ro zur Therapie von Hepatitis geeignet sind. Studies have further shown that pharmaceutical Preparations containing ginsenoside Ro for the treatment of hepatitis are suitable.
Erfindungsgemäße Präparate mit einem Gehalt an den Ginsenosiden Rb1 und Rg1 sind vorzugsweise zur Therapie von Aggressionen, solche mit einem Gehalt an dem Ginsenosid Rb zur Therapie bei Herzerkrankungen und Präparate mit einem Gehalt an den Ginsenosiden Rb1 und Rg3 zum Schutz von Nervenzellen geeignet. Preparations according to the invention containing the ginsenosides Rb1 and Rg1 are preferred for the treatment of aggressions, those with a content on the ginsenoside Rb for therapy for heart diseases and preparations with contains the ginsenosides Rb1 and Rg3 to protect nerve cells suitable.
Die erfindungsgemäßen Verwendungen des neuen pharmazeutischen Präparates ergeben sich aus den Merkmalen der Ansprüche 7 bis 28. The uses of the new pharmaceutical Preparation result from the features of claims 7 to 28.
Zweckmäßig ist es, die für die Verpackung einzusetzende Lipidkomposition entsprechend ihrem organspezifischen Targeting, wie es sich aus dem bekannten Stand der Technik ergibt, auszuwählen und in Übereinstimmung mit der Targetingstrategie darin das Ginsenosid oder das Gemisch an Ginsenosiden mit der betreffenden organspezifischen Wirkung zu verpacken. It is expedient to use the lipid composition to be used for the packaging according to their organ-specific targeting, as it results from the known prior art, select and in accordance with the targeting strategy in it the ginsenoside or the mixture of ginsenosides with the relevant organ-specific effect.
Die Verpackung der Ginsenoside kann auch nach den sich aus dem DE 198 52 928 C1 ergebenden technischen Lösungen erfolgen. The packaging of the ginsenosides can also be found in DE 198 52 928 C1 resulting technical solutions.
Des weiteren ist es möglich, die Ginsenoside oder deren Mischungen nach der bekannten und in der Literatur beschriebenen Kavitator-Technologie zu verpacken. Furthermore, it is possible to use the ginsenosides or their mixtures after known and described in the literature cavitator technology packaging.
Insgesamt bieten die erfindungsgemäßen Lösungen völlig neue und kostengünstige Ansatzpunkte für das therapeutische Anwendungsfeld der einzelnen Ginsenoside und deren Kompositionen und die Erhöhung der therapeutischen Effizienz pharmazeutischer Präparate durch deren Konzentration am Wirkungsort. Overall, the solutions according to the invention offer completely new and inexpensive starting points for the therapeutic field of application of individual ginsenosides and their compositions and increasing the therapeutic efficiency of pharmaceutical preparations through their Concentration at the place of action.
Claims (28)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2001158281 DE10158281A1 (en) | 2001-11-19 | 2001-11-19 | Pharmaceutical preparation comprises ginsenoside enclosed in micro-shell, e.g. liposome, providing targeted and controlled delivery, useful e.g. in treatment of liver tumors, diabetes mellitus or hypertension |
PCT/DE2002/004281 WO2003045410A1 (en) | 2001-11-19 | 2002-11-18 | Pharmaceutical preparation containing micro-encapsulated or nano-encapsulated ginsenosides |
AU2002358418A AU2002358418A1 (en) | 2001-11-19 | 2002-11-18 | Pharmaceutical preparation containing micro-encapsulated or nano-encapsulated ginsenosides |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2001158281 DE10158281A1 (en) | 2001-11-19 | 2001-11-19 | Pharmaceutical preparation comprises ginsenoside enclosed in micro-shell, e.g. liposome, providing targeted and controlled delivery, useful e.g. in treatment of liver tumors, diabetes mellitus or hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10158281A1 true DE10158281A1 (en) | 2003-05-28 |
Family
ID=7707206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2001158281 Withdrawn DE10158281A1 (en) | 2001-11-19 | 2001-11-19 | Pharmaceutical preparation comprises ginsenoside enclosed in micro-shell, e.g. liposome, providing targeted and controlled delivery, useful e.g. in treatment of liver tumors, diabetes mellitus or hypertension |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002358418A1 (en) |
DE (1) | DE10158281A1 (en) |
WO (1) | WO2003045410A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006113495A2 (en) * | 2005-04-15 | 2006-10-26 | Hui-Ling Chen | Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof |
DE102005052005B4 (en) * | 2005-10-31 | 2007-10-18 | Infineon Technologies Ag | Processor arrangement |
EP2036566A1 (en) * | 2006-06-09 | 2009-03-18 | Shanghai Innovative Research Center Of Traditional Chinese Medicine | Use of 20(s)-protopanoxadiol in manufacture of antidepressants |
US8765695B2 (en) * | 2007-03-12 | 2014-07-01 | Jecui Health Industry Corp. Ltd. | Use of ginsenoside RG1, its metabolites ginsenoside RH1 and/or PPT |
EP3973965A4 (en) * | 2019-06-06 | 2022-10-05 | China Pharmaceutical University | Medical use of pentacyclic triterpenoid saponin compound and pharmaceutical composition thereof |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100411623C (en) * | 2004-09-08 | 2008-08-20 | 李泽琳 | Use for treating AIDS from ginseng saponin |
US8394776B2 (en) | 2007-01-16 | 2013-03-12 | Chengdu Di'ao Jiuhong Pharmaceutical Factor | Use of ursolic acid saponin,oleanolic acid saponin in preparation of increasing leucocytes and/or platelet medicine |
KR100842070B1 (en) | 2007-04-09 | 2008-06-30 | 박준원 | Nano platinum ginsenoside particle and production method thereof |
KR20110007473A (en) * | 2009-07-16 | 2011-01-24 | 씨제이제일제당 (주) | Anti-hypertensive composition comprising of ginsenoside fraction |
CN106924427A (en) * | 2017-03-24 | 2017-07-07 | 成都海青生物科技有限公司 | It is a kind of effectively to treat Chinese medicine composition of diabete and preparation method thereof |
CN108014118B (en) * | 2017-12-25 | 2019-12-03 | 上海中医药大学 | A kind of purposes of notoginsenoside Ft1 |
EP4180445A1 (en) * | 2020-07-07 | 2023-05-17 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Pentacyclic triterpenoid glycoside compound, and preparation method therefor and use thereof |
CN114159450B (en) * | 2020-09-10 | 2023-10-27 | 上海交通大学 | Use of protopanaxadiol compounds for treating physical dependence, mental dependence and addiction of pain and addiction substances |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5646817A (en) * | 1979-09-27 | 1981-04-28 | Ryuta Ito | Saponin antitumor agent |
JPH09241166A (en) * | 1996-03-06 | 1997-09-16 | Kureha Chem Ind Co Ltd | Synthesis suppressant containing ginsenosides for protein belonging to hsp60 family |
WO2002007732A2 (en) * | 2000-07-26 | 2002-01-31 | Cambridge University Technical Services Limited | Use of panaxatriol for stimulation angiogenesis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2179042B (en) * | 1985-07-22 | 1988-11-23 | Takeda Chemical Industries Ltd | A process of producing ginsenoside-rd |
KR100192678B1 (en) * | 1995-06-07 | 1999-06-15 | 손경식 | Processed ginseng product having an increased pharmacological activity |
US5891465A (en) * | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
DE19852928C1 (en) * | 1998-11-17 | 2000-08-03 | Steffen Panzner | Structures in the form of hollow spheres |
JP2000191539A (en) * | 1998-12-22 | 2000-07-11 | Japan Science & Technology Corp | BRAIN CELL OR NERVE CELL-PROTECTING AGENT COMPRISING GINSENOSIDE Rb1 |
US6340478B1 (en) * | 1999-06-07 | 2002-01-22 | Bio Dar Ltd. | Microencapsulated and controlled-release herbal formulations |
GB0105613D0 (en) * | 2001-03-07 | 2001-04-25 | Univ Cambridge Tech | Pharmaceutically effective compounds and their use |
-
2001
- 2001-11-19 DE DE2001158281 patent/DE10158281A1/en not_active Withdrawn
-
2002
- 2002-11-18 AU AU2002358418A patent/AU2002358418A1/en not_active Abandoned
- 2002-11-18 WO PCT/DE2002/004281 patent/WO2003045410A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5646817A (en) * | 1979-09-27 | 1981-04-28 | Ryuta Ito | Saponin antitumor agent |
JPH09241166A (en) * | 1996-03-06 | 1997-09-16 | Kureha Chem Ind Co Ltd | Synthesis suppressant containing ginsenosides for protein belonging to hsp60 family |
WO2002007732A2 (en) * | 2000-07-26 | 2002-01-31 | Cambridge University Technical Services Limited | Use of panaxatriol for stimulation angiogenesis |
Non-Patent Citations (1)
Title |
---|
Fitoterapia 57(4), 1986, 217-222 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006113495A2 (en) * | 2005-04-15 | 2006-10-26 | Hui-Ling Chen | Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof |
WO2006113495A3 (en) * | 2005-04-15 | 2007-06-07 | Hui-Ling Chen | Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof |
DE102005052005B4 (en) * | 2005-10-31 | 2007-10-18 | Infineon Technologies Ag | Processor arrangement |
EP2036566A1 (en) * | 2006-06-09 | 2009-03-18 | Shanghai Innovative Research Center Of Traditional Chinese Medicine | Use of 20(s)-protopanoxadiol in manufacture of antidepressants |
EP2036566A4 (en) * | 2006-06-09 | 2011-06-15 | Shanghai Innovative Res Ct Of Traditional Chinese Medicine | Use of 20(s)-protopanoxadiol in manufacture of antidepressants |
US8765695B2 (en) * | 2007-03-12 | 2014-07-01 | Jecui Health Industry Corp. Ltd. | Use of ginsenoside RG1, its metabolites ginsenoside RH1 and/or PPT |
EP3973965A4 (en) * | 2019-06-06 | 2022-10-05 | China Pharmaceutical University | Medical use of pentacyclic triterpenoid saponin compound and pharmaceutical composition thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2002358418A1 (en) | 2003-06-10 |
WO2003045410A1 (en) | 2003-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10158281A1 (en) | Pharmaceutical preparation comprises ginsenoside enclosed in micro-shell, e.g. liposome, providing targeted and controlled delivery, useful e.g. in treatment of liver tumors, diabetes mellitus or hypertension | |
DE19838848A1 (en) | Composition containing pyrrolizidine alkaloid-free petasites | |
DE3207841A1 (en) | ADJUVANS PREPARATION | |
WO2005076750A2 (en) | A novel synergistic herbal formulation for diabetes cure | |
EP0869807B1 (en) | Use of a medicament and use of mixture of substances to produce a medicament | |
WO2000048445A2 (en) | Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence | |
WO1992004036A1 (en) | Kava extract, method of preparing the extract, and its use | |
US6428823B1 (en) | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L | |
DE2325070A1 (en) | PHARMACEUTICAL PREPARATIONS FOR THE PROPHYLAXIS AND TREATMENT OF CAPILLARY VENUS DISEASES | |
EP1001756B1 (en) | Synergistically acting compositions for selectively combating tumor tissue | |
EP2229950B1 (en) | Use of plants of the sideritis genus and extracts from same for treating attention deficit/hyperactivity disorder | |
EP0403575B1 (en) | Acyl carnitine for the treatment and prevention of virus infections | |
EP1839668B1 (en) | Use of Nisyline in the treatment of Herpes labialis and Herpes genitalis | |
EP0845983A2 (en) | Pharmaceutical composition with trypanocidal properties | |
DE3840946A1 (en) | USE OF ALUMINUM POTASSIUM SULFATE AND / OR 1 OR MORE OF ITS HYDRATES | |
DE102022115137A1 (en) | Composition with hepatoprotective effect | |
DE10238161A1 (en) | Mucosal or topical administration of minerals, e.g. for treating muscle spasms, psoriasis or osteoporosis or promoting wound healing, comprises direct application of mineral solution from ampoule | |
EP1886694A1 (en) | Peroral formulation of dienogest and ethinylestradiol for contraception | |
DE3511236C2 (en) | ||
Aderjan et al. | Poisoning by diphenhydramine—forensic-toxicologic interpretation of analytic results | |
WO1998017229A2 (en) | Medicament | |
Aderjan et al. | Vergiftungen mit Diphenhydramin—Forensisch-toxikologische Beurteilung von Analysenbefunden | |
Ekpo et al. | Using the BALB/c asthmatic mouse model to investigate the effects of hydrocortisone and a herbal asthma medicine on animal weight | |
Tyagi et al. | EVIDENCE-BASED CLASSICAL AND ETHANOMEDICINAL REVIEW ON HOLOPTELEA INTEGRIFOLIA (ROXB.) PLANCH.(CHIRABILVA) | |
DE60206467T2 (en) | Detoxifying phytotherapeutic composition of two plant extracts and process for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8139 | Disposal/non-payment of the annual fee |